Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?

D. Ahishakiye; Sophie Lorent; Daniel De Backer; Philippe Gottignies; Jean Louis Vincent

doi:10.1016/j.jcrc.2009.03.009

Back

Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?

Article 2009 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2007

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*

Derek C. Angus, Walter T. Linde‐Zwirble, Gilles Clermont, Daniel Ball, Bruce R. Basson, E. Wesley Ely, Pierre‐François Laterre, Jean Louis Vincent, Gordon R. Bernard, Ben van Hout

Article2006

Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis

Daniel De Backer, Colin Verdant, Marialuisa Chierego, Marc Koch, Antonino Gullo, Jean Louis Vincent

Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?

Discussion(0)

Related publications

Drotrecogin alfa (activated): the treatment for severe sepsis?

Drotrecogin alfa (activated) in the treatment of severe sepsis

Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*

Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis